David A. Siegel Pliant Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 157,800 shares of PLRX stock, worth $2.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
157,800
Previous 189,700
16.82%
Holding current value
$2.1 Million
Previous $2.04 Million
13.29%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding PLRX
# of Institutions
168Shares Held
63.2MCall Options Held
245KPut Options Held
373K-
Deep Track Capital, LP Greenwich, CT5.97MShares$79.4 Million2.47% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$66.1 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.83MShares$64.3 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.53MShares$46.9 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.2MShares$42.5 Million2.34% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $647M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...